business Research report
10 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by Ruth Weigle
Scoop.it!

Lip Cancer Market- Clinical Trials Review

Lip Cancer Market- Clinical Trials Review | business Research report | Scoop.it
Lip Cancer Global Clinical Trials Review, H1, 2014 is a market research report available at US $2500 for a Single User PDF License from RnR Market Research Reports Library.
Ruth Weigle's insight:

The Report “Lip Cancer Global Clinical Trials Review, H1, 2014″ by GlobalData is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with “Lip Cancer Global Clinical Trials Review, H1, 2014″ in subject line and your contact details to purchase this report or get your questions answered.

“Lip Cancer Global Clinical Trials Review, H1, 2014″ provides data on the Lip Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lip Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lip Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Researcher’s team of industry experts.

Request Sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=153343 .

Scope

Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nationsClinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor typeListings of discontinued trials (suspended, withdrawn and terminated)

Complete report is available @ http://www.rnrmarketresearch.com/lip-cancer-global-clinical-trials-review-h1-2014-market-report.html . Read more on “Lip Cancer Global Clinical Trials Review, H1, 2014” report below.

Reasons to buy

Understand the dynamics of a particular indication in a condensed mannerAbridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many moreObtain discontinued trial listing for trials across the globeEspy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Lip Cancer 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Lip Cancer to Oncology Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Lip Cancer to Oncology Clinical Trials 17
Clinical Trials by Phase 18
In Progress Trials by Phase 19
Clinical Trials by Trial Status 20
Clinical Trials by End Point Status 21
Unaccomplished Trials of Lip Cancer 22
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Drugs 26
Clinical Trial Overview of Top Institutes / Government 27
National Cancer Institute 27
Clinical Trial Overview of National Cancer Institute 27
University of Washington 30
Clinical Trial Overview of University of Washington 30
Roswell Park Cancer Institute 31
Clinical Trial Overview of Roswell Park Cancer Institute 31
Stanford University 32
Clinical Trial Overview of Stanford University 32
Ohio State University Comprehensive Cancer Center 33
Clinical Trial Overview of Ohio State University Comprehensive Cancer Center 33
The University of Chicago 34
Clinical Trial Overview of The University of Chicago 34
Case Comprehensive Cancer Center 35
Clinical Trial Overview of Case Comprehensive Cancer Center 35
University of Kentucky 36
Clinical Trial Overview of University of Kentucky 36
The Ohio State University 37
Clinical Trial Overview of The Ohio State University 37
Washington University School of Medicine 38
Clinical Trial Overview of Washington University School of Medicine 38
Five Key Clinical Profiles 39
Appendix 118
Abbreviations 118
Definitions 118
Research Methodology 119
Secondary Research 119
Contact Us 120
Disclaimer 120
Source 121

For further information on “Lip Cancer Global Clinical Trials Review, H1, 2014   ” report OR for any other business research / market intelligence need on the ‘Clinical Trial’ market (http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/clinical-trial .), contact sales@rnrmarketresearch.com / Call +1 888 391 5441.

 

About Us:

RnRMarketResearch.com is an online market research reports library of 250,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers. RnR Market Research also offers company data, country profiles, trends, information and analysis on the sector of your interest.

 

You can also reach us @

http://rnrmarketresearch.blogspot.in/

http://www.rnrmarketresearch.com/blog/

http://www.facebook.com/pages/RnR-Market-Research/413488545356345

https://plus.google.com/u/0/104156468549256253075/

https://twitter.com/#!/RnRMR

http://www.dailymotion.com/rnrmarketresearch

http://www.youtube.com/user/rnrmarketresearch

http://www.slideshare.net/rnrmarketresearch3/

more...
No comment yet.
Scooped by Ruth Weigle
Scoop.it!

China Quetiapine Industry Forecast to 2018

China Quetiapine Industry Forecast to 2018 | business Research report | Scoop.it
Investigation Report on China Quetiapine Market, 2009-2018 published in Feb 2014 Available for US $ 1800 at ChinaMarketResearchReports.com - Buy Now or Inquire about this report online.
Ruth Weigle's insight:

The report “Investigation Report on China Quetiapine Market, 2009-2018″ by China Research and Intelligence is now available at chinamarketresearchreports.com. Contact sales@chinamarketresearchreports.com with Research Report on Investigation Report on China Quetiapine Market, 2009-2018 in subject line and your contact details to purchase this report or get your questions answered.

The collection of ‘Life Sciences’ market research reports has a new addition of “Investigation Report on China Quetiapine Market, 2009-2018”On chinamarketresearchreports.com . Schizophrenia is a common mental disorder. As a chronic disease, schizophrenia can lead to recurrent or persistent symptoms in most patients' whole life. As Chinese economy and society develops, life and work here has become increasingly stressful. As a result, recurrence rate of schizophrenia has also increased. Statistics shows that the number of schizophrene in China has exceeded 10 million by the end of 2013, and it is still rising year after year.

Quetiapine is originally developed by Astra Zeneca and has curative effect on various schizophrenic symptoms. It was firstly approved to the U.K. market in July 1997 and to the U.S. market on September 26, 1997 by FDA with the trade name "Seroquel". Patent of this product expired on March 26, 2012. To prolong its life cycle, longacting release formulation of quetiapine developed by Astra Zeneca was approved to the U.S. market on May 17, 2007 with the trade name "Seroquel XR", which extends its patent protection to November 28, 2017. After that it has come into markets of several countries sequentially, such as Germany and China.

Inquire this Report before buying @ http://www.chinamarketresearchreports.com/contacts/inquire-before-buy.php?name=114731.

In 2012, global sales revenue of Seroquel and Seroquel XR was USD 2,803 million, of which the former dropped by 70% to USD 1,294 million while the later increased to USD 1,509 million.

The moment the patent of Seroquel expired, it became target of many generic drug manufacturers.

On March 22, 2012, the U.K. High Court ruled that the patent of Seroquel XR prescription was invalid. However, District Court of New Jersey later ruled that patent of Seroquel XR was valid. Consequently, the production of Seroquel generic drug by Anchen, Osmotica, Torrent and Mylan Pharmaceutical Company has violated the patent of Seroquel XR prescription, which expires in 2017.

On March 27, 2012, Teva Pharmaceutical Industries Limited launched generic drugs of Seroquel and Seroquel XL in the U.K. on the same day, Dr. Reddy's Lab from India launched Seroquel generic drug in the U.S. Astra Zeneca permitted Intelli to sell generic drug of Seroquel XL from November 2016.

Quetiapine produced by Astra Zeneca was approved to China in 2000 with the trade name "Seroquel". In the same year, Hunan Dongting Pharmaceutical Co., Ltd. became the first approved manufacturer to produce quetiapine raw material and troche with the brand name "Qi Wei". In 2003, Suzhou Pharmaceutical Group Co., Ltd. was also approved to produce quetiapine raw material and troche with the brand name "Shu Si". Moreover, Chongqing Fuan Pharmaceutical Co., Ltd. and Zhejiang Supor Pharmaceuticals Co., Ltd. received raw material approvals respectively in 2011 and 2012. Many pharmaceutical manufacturers in China have reported quetiapine tablet production, among which Suzhou Pharmaceutical Group Co., Ltd. reported the production of quetiapine sustainedrelease tablets in 2012.

Complete report spread across [40] pages available @ http://www.chinamarketresearchreports.com/114731.html . Read more on “Investigation Report on China Quetiapine Market, 2009-2018” report below.

According to CRI's market investigation, Seroquel produced by Astra Zeneca takes up over 70% of quetiapine market in Chinese sample hospitals, followed by Qi Wei produced by Hunan Dongting Pharmaceutical Co., Ltd. and Shu Si produced by Suzhou Pharmaceutical Group Co., Ltd.

The CAGR of sales value of quetiapine surpassed 25% in Chinese sample hospitals from 2005 to 2012. Its growth rate has been declining slightly since 2010, but an annual growth rate of 10% is basically maintained. Quetiapine is now listed in Guidelines of Mental Illness Treatment in China. It is considered as a firstline drug to treat schizophrenia in Chinese market. Estimation indicates that the number of schizophrene in China will continue to rise in the next few years, leaving huge market space to grow for quetiapine.

Through this report, the readers can acquire the following information:

Incidence of Schizophrenia in ChinaMarket Share of Major Quetiapine Manufacturers in China Sample HospitalsSales price of Quetiapine in China Hospital MarketProduction Status of Quetiapine Generic Drug in ChinaMajor Quetiapine Manufacturers in ChinaProspect of China Quetiapine Market

The following enterprises and people are recommended to purchase this report:

Antischizophrenia Medication ManufacturersMedical Institutions

For further information on “Investigation Report on China Quetiapine Market, 2009-2018” report OR for any other business research / market intelligence need on the ‘Life Sciences’ market (http://www.chinamarketresearchreports.com/cat/life-sciences.html .), contact sales@chinamarketresearchreports.com / Call +1 888 391 5441.

 

more...
No comment yet.
Scooped by Ruth Weigle
Scoop.it!

China Tacrolimus Industry Forecast to 2018

China Tacrolimus Industry Forecast to 2018 | business Research report | Scoop.it
Investigation Report on China Tacrolimus Market, 2009-2018 published in Feb 2014 Available for US $ 1800 at ChinaMarketResearchReports.com - Buy Now or Inquire about this report online.
Ruth Weigle's insight:

The report “Investigation Report on China Tacrolimus Market, 2009-2018″ by China Research and Intelligence is now available at chinamarketresearchreports.com. Contact sales@chinamarketresearchreports.com with Research Report on Investigation Report on China Tacrolimus Market, 2009-2018 in subject line and your contact details to purchase this report or get your questions answered.

The collection of ‘Life Sciences’ market research reports has a new addition of “Investigation Report on China Tacrolimus Market, 2009-2018”On chinamarketresearchreports.com . Tacrolimus, also named as "FK506" and "FR900506", was developed by Fujisawa Pharmaceutical Co., Ltd. (later became Astellas Pharma by merging with Yamanouchi Pharmaceutical Co., Ltd.). In June 1993, it was firstly approved to Japan with the trade name "Prograf". Tacrolimus is an immunosuppressive drug that is used mainly after allogeneic organ transplant to reduce the activity of the patient's immune system and so lower the risk of organ rejection. It was approved by the FDA in 1994. Tacrolimus is sold in markets of several countries and regions now. In 1998, tacrolimus preparation (injection and capsule) was approved to import into China.

Since then, tacrolimus has become a firstline clinical drug to reduce organ rejection after liver and kidney transplantation in China. The sales revenue is also increasing rapidly.

Inquire this Report before buying @ http://www.chinamarketresearchreports.com/contacts/inquire-before-buy.php?name=114729 .

For immunosuppressant is used in transplantation, a relatively special field, it requires high technical standard and large amount of investment in new compound development. The drugs available at present are thus very monopolistic, among which tacrolimus is with the most promising future and highest market value.

Since organ transplantation volume in China is only second to that of the U.S.A., a great amount of immunosuppressant is needed. The Chinese government has chosen this drug as clinicalpreferred basic immunosuppressant. In recent years, the clinical application of tacrolimus continues to expand. It can treat many autoimmune diseases and is approved effective for immune diseases without specific medicine such as rheumatoid arthritis, kidney cirrhosis syndrome, atopic dermatitis and lupus. Therefore, the future is bright for medical use of tacrolimus.

Complete report spread across [40] pages available @ http://www.chinamarketresearchreports.com/114729.html . Read more on “Investigation Report on China Tacrolimus Market, 2009-2018” report below.

Through this report, the readers can acquire the following information:

Market Share of Major Tacrolimus Manufacturers in China Sample HospitalsSales price of Tacrolimus in China Hospital MarketMajor Tacrolimus Manufacturers in ChinaShare of Tacrolimus in Different Dosage Forms in China Hospital MarketProspect of China Tacrolimus Market

The following enterprises and people are recommended to purchase this report:

Tacrolimus APIs and Finished Product ManufacturersMedical InstitutionsInvestors/Research Institutes Focusing on Tacrolimus Market

For further information on “Investigation Report on China Tacrolimus Market, 2009-2018” report OR for any other business research / market intelligence need on the ‘Life Sciences’ market (http://www.chinamarketresearchreports.com/cat/life-sciences.html .), contact sales@chinamarketresearchreports.com / Call +1 888 391 5441.

more...
No comment yet.
Scooped by Ruth Weigle
Scoop.it!

Australia Coal Mining Market to Grow at a CAGR of 4.4% to 2022

Australia Coal Mining Market to Grow at a CAGR of 4.4% to 2022 | business Research report | Scoop.it

Coal Mining in Australia to 2020 is a market research report available at US $1495 for a Single User PDF License from RnR Market Research Reports Library.

Ruth Weigle's insight:

The Report “Coal Mining in Australia to 2020″ by Timetric is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with “Coal Mining in Australia to 2020″ in subject line and your contact details to purchase this report or get your questions answered.

Australia is one of the world’s largest producers and exporter of coal with production estimated at 476.5 million tons (Mt) in 2013, further projected to reach 635.9Mt in 2020, representative of a CAGR of 4.4%. Substantial production over the forecast period is likely due to capacity extensions and new projects. Projects such as the China First coal project, the Alpha coal project, the Wandoan project, and the South Galilee project located in the state of Queensland are some of the largest, with capacities of 40Mt, 30Mt, 22Mt and 13.6Mt respectively. The country’s abundant and high-quality coal deposits are widely distributed across all the country’s states and the Northern Territory.

Purchase this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=150488 .

Scope

The report contains an overview of the Australian coal mining industry together with the its growth factors and restraints. It also provides detailed information about production, prices, production by grade, basin and mining methods, reserves, reserves by grade and regions, major producing mines, competitive landscape, major exploration and development projects, consumption, consumption by type and trade. Also included is the country’s fiscal regime, which includes governing bodies and relevant laws, rights and obligations of the mining companies, as well as key fiscal terms.

Complete report is available @ http://www.rnrmarketresearch.com/coal-mining-in-australia-to-2020-market-report.html . Read more on “Coal Mining in Australia to 2020” report below.

The ‘Coal Mining in Australia to 2020′ report provides historical and forecast data on coal production (by grade), reserves, consumption (by type) and trade (also by type) to 2020. The trade section provides information on export volume (to destination countries) as well as imports.

This report includes drivers and restraints affecting the industry, profiles of major coal mining companies, information on the major active, development and exploration projects, and the fiscal regime and regulations governing the industry. The report provides a comprehensive coverage of Australia’s coal mining industry.

Key highlights

New South Wales and Queensland dominate Australia’s black coal production, although smaller quantities of black coal originate from Western Australia, South Australia and Tasmania.Significant black coal deposits are located in the Bowen-Surat basin in Queensland and Sydney basin in New South Wales.By 2015, expansion plans at the major ports in Queensland and New South Wales will increase the total export handling capacity to 515 million tons per annum (Mtpa) from 456Mtpa in 2011.Australia’s proven coal reserves amounted to around 76.4billion tons (bt) at the end of 2012, representing 9% of proven global coal proven reserves.

Reasons to buy

Gain an understanding of the Australian coal mining industry, the relevant drivers and restraining factors, historical and forecast production, consumption and trade data and the fiscal regime.

For further information on “Coal Mining in Australia to 2020” report OR for any other business research / market intelligence need on the ‘Coal Mining’ market (www.rnrmarketresearch.com/reports/energy-power/mining/coal-mining .), contact sales@rnrmarketresearch.com / Call +1 888 391 5441.

 

About Us:

RnRMarketResearch.com is an online market research reports library of 250,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers. RnR Market Research also offers company data, country profiles, trends, information and analysis on the sector of your interest.

 

You can also reach us @

http://rnrmarketresearch.blogspot.in/

http://www.rnrmarketresearch.com/blog/

http://www.facebook.com/pages/RnR-Market-Research/413488545356345

https://plus.google.com/u/0/104156468549256253075/

https://twitter.com/#!/RnRMR

http://www.dailymotion.com/rnrmarketresearch

http://www.youtube.com/user/rnrmarketresearch

http://www.slideshare.net/rnrmarketresearch3/

more...
No comment yet.
Scooped by Ruth Weigle
Scoop.it!

2022 Germany Obesity Market Forecasts and Analysis

2022 Germany Obesity Market Forecasts and Analysis | business Research report | Scoop.it

PharmaPoint: Obesity - Germany Drug Forecast and Market Analysis to 2022 is a market research report available at US $4995 for a Single User PDF License from RnR Market Research Reports Library.

Ruth Weigle's insight:

The Report “PharmaPoint: Obesity – Germany Drug Forecast and Market Analysis to 2022″ by GlobalData is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with “PharmaPoint: Obesity – Germany Drug Forecast and Market Analysis to 2022″ in subject line and your contact details to purchase this report or get your questions answered.

After a more than decade long dormancy, the Obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade.

The only drug available for the treatment of obesity in Germany is Xenical, which is seeing a steady decrease in patient use. This is a severely underserved market, as there are simply no anti-obesity drugs available. According to Researcher’s primary research, the percentage of patients taking Xenical is extremely low at approximately only 5% of the total patients who are overweight or obese.

Request Sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=150298 .

Scope

Overview of Obesity including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.Detailed information on the key drugs in Germany including product description, safety and efficacy profiles as well as a SWOT analysis.Sales forecast for the top drugs in Germany from 2012-2022.Analysis of the impact of key events as well the drivers and restraints affecting the Germany Obesity market.

Complete report is available @ http://www.rnrmarketresearch.com/pharmapoint-obesity-germany-drug-forecast-and-market-analysis-to-2022-market-report.html . Read more on “PharmaPoint: Obesity – Germany Drug Forecast and Market Analysis to 2022” report below.

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return.Stay ahead of the competition by understanding the changing competitive landscape for Obesity.Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.Make more informed business decisions from insightful and in-depth analysis of drug performance.Obtain sales forecast for drugs from 2012-2022 in Germany.

 

Table of Contents

1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 9

2 Introduction 10
2.1 Catalyst 11
2.2 Related Reports 12

3 Disease Overview 14
3.1 Etiology and Pathophysiology 16
3.1.1 Etiology 16
3.1.2 Pathophysiology 17
3.1.3 Prognosis 17
3.1.4 Quality of Life 18
3.2 Symptoms 18

4 Disease Management 19
4.1 Treatment Overview 19
4.2 Germany 24
4.2.1 Diagnosis 24
4.2.2 Clinical Practice 26

5 Competitive Assessment 32
5.1 Overview 32
5.2 Strategic Competitor Assessment 36
5.3 Product Profiles: Drugs 38
5.3.1 Xenical (orlistat) 38
5.3.2 Belviq (lorcaserin) 41
5.3.3 Oblean (cetilistat) 46

6 Opportunity and Unmet Need 49
6.1 Overview 49
6.2 A Drug with Greater Than 10% Average Weight Loss 50
6.2.1 Unmet Need 50
6.2.2 Gap Analysis 51
6.2.3 Opportunity 52
6.3 A Drug with Increased Safety and Tolerability 52
6.3.1 Unmet Need 52
6.3.2 Gap Analysis 53
6.3.3 Opportunity 53
6.4 Reimbursement by Private and Public Payers 53
6.4.1 Unmet Need 53
6.4.2 Gap Analysis 55
6.4.3 Opportunity 55
6.5 Increased Physician Education 55
6.5.1 Unmet Need 55
6.5.2 Gap Analysis 56
6.5.3 Opportunity 56
6.6 Increased Drug-Treatment Rate 57
6.6.1 Unmet Need 57
6.6.2 Gap Analysis 57
6.6.3 Opportunity 58
6.7 Improved Guidelines 58
6.7.1 Unmet Need 58
6.7.2 Gap Analysis 59
6.7.3 Opportunity 59
6.8 Improved Approach to Diagnosis 59
6.8.1 Unmet Need 59
6.8.2 Gap Analysis 60
6.8.3 Opportunity 60

7 Pipeline Assessment 61
7.1 Overview 61
7.2 Promising Drugs in Clinical Development 64
7.2.1 Contrave 67
7.2.2 Victoza (liraglutide) 72
7.2.3 Velneperit 77
7.2.4 Empatic 81

8 Market Outlook 86
8.1 Germany 87
8.1.1 Forecast 87
8.1.2 Key Events 91
8.1.3 Drivers and Barriers 92

9 Appendix 94
9.1 Bibliography 94
9.2 Abbreviations 100
9.3 Research Methodology 102
9.4 Forecasting Methodology 102
9.4.1 Percent Drug-Treated Obesity Patients 103
9.4.2 Drugs Included in Each Therapeutic Class 103
9.4.3 Launch and Patent Expiry Dates 104
9.4.4 General Pricing Assumptions 104
9.4.5 Individual Drug Assumptions 105
9.4.6 Generic Erosion 108
9.4.7 Pricing of Pipeline Agents 108
9.5 Physicians, Specialists, and Payers Included in This Study 109
9.6 About the Authors 112
9.6.1 Analysts 112
9.6.2 Therapy Director - CVMD and Infectious Disease 113
9.6.3 Director - Medical Devices 113
9.6.4 Global Head of Healthcare 114
9.8 Disclaimer 115

 

For further information on “PharmaPoint: Obesity – Germany Drug Forecast and Market Analysis to 2022” report OR for any other business research / market intelligence need on the ‘Obesity Drugs’ market (http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/obesity-drugs .), contact sales@rnrmarketresearch.com / Call +1 888 391 5441.

 

About Us:

RnRMarketResearch.com is an online market research reports library of 250,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers. RnR Market Research also offers company data, country profiles, trends, information and analysis on the sector of your interest.

 

You can also reach us @

http://rnrmarketresearch.blogspot.in/

http://www.rnrmarketresearch.com/blog/

http://www.facebook.com/pages/RnR-Market-Research/413488545356345

https://plus.google.com/u/0/104156468549256253075/

https://twitter.com/#!/RnRMR

http://www.dailymotion.com/rnrmarketresearch

http://www.youtube.com/user/rnrmarketresearch

http://www.slideshare.net/rnrmarketresearch3/

more...
No comment yet.
Scooped by Ruth Weigle
Scoop.it!

2022 America Obesity Market Forecasts and Analysis

2022 America Obesity Market Forecasts and Analysis | business Research report | Scoop.it

PharmaPoint: Obesity - US Drug Forecast and Market Analysis to 2022 is a market research report available at US $4995 for a Single User PDF License from RnR Market Research Reports Library.

Ruth Weigle's insight:

The Report “PharmaPoint: Obesity – US Drug Forecast and Market Analysis to 2022″ by GlobalData is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with “PharmaPoint: Obesity – US Drug Forecast and Market Analysis to 2022″ in subject line and your contact details to purchase this report or get your questions answered.

After a more than decade long dormancy, the Obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade.

New US entrants are expected to obtain significant market share during the forecast period, as this is a key potential market with an obese population exceeding that of Europe, Japan, and Canada combined. With a severely underserved market, any new players will most certainly have a large potential patient share to gain. The expected drivers of market growth are an increased awareness of the importance of preemptive treatment and sustained management of the condition.

Request Sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=150296 .

Scope

Overview of Obesity including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.Sales forecast for the top drugs in the US from 2012-2022.Analysis of the impact of key events as well the drivers and restraints affecting the US Obesity market.

Complete report is available @ http://www.rnrmarketresearch.com/pharmapoint-obesity-us-drug-forecast-and-market-analysis-to-2022-market-report.html . Read more on “PharmaPoint: Obesity – US Drug Forecast and Market Analysis to 2022” report below.

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return.Stay ahead of the competition by understanding the changing competitive landscape for Obesity.Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.Make more informed business decisions from insightful and in-depth analysis of drug performance.Obtain sales forecast for drugs from 2012-2022 in the US.

Table of Contents

1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 9

2 Introduction 10
2.1 Catalyst 11
2.2 Related Reports 12

3 Disease Overview 14
3.1 Etiology and Pathophysiology 16
3.1.1 Etiology 16
3.1.2 Pathophysiology 17
3.1.3 Prognosis 17
3.1.4 Quality of Life 18
3.2 Symptoms 18

4 Disease Management 19
4.1 Treatment Overview 19
4.2 US 24
4.2.1 Diagnosis 24
4.2.2 Clinical Practice 25

5 Competitive Assessment 29
5.1 Overview 29
5.2 Strategic Competitor Assessment 33
5.3 Product Profiles: Drugs 35
5.3.1 Phentermine 35
5.3.2 Xenical (orlistat) 39
5.3.3 Qsymia (phentermine-topiramate) 42
5.3.4 Belviq (lorcaserin) 49
5.3.5 Topiramate 54
5.3.6 Oblean (cetilistat) 58

6 Opportunity and Unmet Need 61
6.1 Overview 61
6.2 A Drug with Greater Than 10% Average Weight Loss 62
6.2.1 Unmet Need 62
6.2.2 Gap Analysis 63
6.2.3 Opportunity 64
6.3 A Drug with Increased Safety and Tolerability 64
6.3.1 Unmet Need 64
6.3.2 Gap Analysis 65
6.3.3 Opportunity 65
6.4 Reimbursement by Private and Public Payers 66
6.4.1 Unmet Need 66
6.4.2 Gap Analysis 67
6.4.3 Opportunity 67
6.5 Increased Physician Education 68
6.5.1 Unmet Need 68
6.5.2 Gap Analysis 69
6.5.3 Opportunity 69
6.6 Increased Drug-Treatment Rate 69
6.6.1 Unmet Need 69
6.6.2 Gap Analysis 70
6.6.3 Opportunity 70
6.7 Improved Guidelines 70
6.7.1 Unmet Need 70
6.7.2 Gap Analysis 71
6.7.3 Opportunity 71
6.8 Improved Approach to Diagnosis 72
6.8.1 Unmet Need 72
6.8.2 Gap Analysis 72
6.8.3 Opportunity 72

7 Pipeline Assessment 73
7.1 Overview 73
7.2 Promising Drugs in Clinical Development 76
7.2.1 Contrave 79
7.2.2 Victoza (liraglutide) 83
7.2.3 Velneperit 89
7.2.4 Empatic 93

8 Market Outlook 98
8.1 United States 99
8.1.1 Forecast 99
8.1.2 Key Events 103
8.1.3 Drivers and Barriers 104

9 Appendix 108
9.1 Bibliography 108
9.2 Abbreviations 115
9.3 Research Methodology 117
9.4 Forecasting Methodology 117
9.4.1 Percent Drug-Treated Obesity Patients 118
9.4.2 Drugs Included in Each Therapeutic Class 118
9.4.3 Launch and Patent Expiry Dates 119
9.4.4 General Pricing Assumptions 119
9.4.5 Individual Drug Assumptions 120
9.4.6 Generic Erosion 123
9.4.7 Pricing of Pipeline Agents 123
9.5 Physicians, Specialists, and Payers Included in This Study 124
9.6 About the Authors 127
9.6.1 Analysts 127
9.6.2 Therapy Director - CVMD and Infectious Disease 128
9.6.3 Director - Medical Devices 128
9.6.4 Global Head of Healthcare 129
9.8 Disclaimer 130

 

For further information on “PharmaPoint: Obesity – US Drug Forecast and Market Analysis to 2022” report OR for any other business research / market intelligence need on the ‘Obesity Drugs’ market (http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/obesity-drugs . ), contact sales@rnrmarketresearch.com / Call +1 888 391 5441.

 

About Us:

RnRMarketResearch.com is an online market research reports library of 250,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers. RnR Market Research also offers company data, country profiles, trends, information and analysis on the sector of your interest.

 

You can also reach us @

http://rnrmarketresearch.blogspot.in/

http://www.rnrmarketresearch.com/blog/

http://www.facebook.com/pages/RnR-Market-Research/413488545356345

https://plus.google.com/u/0/104156468549256253075/

https://twitter.com/#!/RnRMR

http://www.dailymotion.com/rnrmarketresearch

http://www.youtube.com/user/rnrmarketresearch

http://www.slideshare.net/rnrmarketresearch3/

more...
No comment yet.
Scooped by Ruth Weigle
Scoop.it!

Cranio Maxillofacial Fixation Industry (CMF) 2020 Forecasts

Cranio Maxillofacial Fixation Industry (CMF) 2020 Forecasts | business Research report | Scoop.it

North America Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020 is a market research report available at US $3000 for a Single User PDF License from RnR Market Research Reports Library.

Ruth Weigle's insight:

The Report “North America Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020″ by GlobalData is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with “North America Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020″ in subject line and your contact details to purchase this report or get your questions answered.

“North America Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020″, provides key market data on the North America Cranio Maxillofacial Fixation (CMF) market. The report provides value, in millions of US dollars, and volume (in units) and average price data (in US dollars), within market categories Cranio Maxillofacial Fixators and Distraction Systems.

The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Cranio Maxillofacial Fixation (CMF) market wherever available.

The data in the report is derived from dynamic market forecast models. Researcher uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible.

Request Sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=153386 .

The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers.

Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases).

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Complete report is available @ http://www.rnrmarketresearch.com/north-america-cranio-maxillofacial-fixation-cmf-market-outlook-to-2020-market-report.html .  Read more on “North America Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020” report below.

Scope

Market size for Cranio Maxillofacial Fixation (CMF) market categories Cranio Maxillofacial Fixators and Distraction Systems.Annualized market revenues (USD million), volume (units) and average selling price ($) data for each of the market categories. Data is provided from 2005 to 2012 and forecast to 2020.2012 company shares and distribution shares data for each of the market categories.Global corporate-level profiles of key companies operating within the North America Cranio Maxillofacial Fixation (CMF) market.Key players covered include DePuy Companies, Stryker Corporation, Biomet, Inc., KLS Martin, L.P., OsteoMed, LLC and Solco Biomedical Co., Ltd.

Reasons to buy

Develop business strategies by identifying the key market segments poised for strong growth in the future.Develop market-entry and market expansion strategies.Design competition strategies by identifying who-stands-where in the market.Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.What are the key distribution channels and what’s the most preferred mode of product distribution Identify, understand and capitalize.

For further information on “North America Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020” report OR for any other business research / market intelligence need on the ‘Orthopedic Device’ market (http://www.rnrmarketresearch.com/reports/life-sciences/medical-devices/orthopedic-device .), contact sales@rnrmarketresearch.com / Call +1 888 391 5441.

 

About Us:

RnRMarketResearch.com is an online market research reports library of 250,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers. RnR Market Research also offers company data, country profiles, trends, information and analysis on the sector of your interest.

 

You can also reach us @

http://rnrmarketresearch.blogspot.in/

http://www.rnrmarketresearch.com/blog/

http://www.facebook.com/pages/RnR-Market-Research/413488545356345

https://plus.google.com/u/0/104156468549256253075/

https://twitter.com/#!/RnRMR

http://www.dailymotion.com/rnrmarketresearch

http://www.youtube.com/user/rnrmarketresearch

http://www.slideshare.net/rnrmarketresearch3/

more...
No comment yet.
Scooped by Ruth Weigle
Scoop.it!

China Pemetrexed Industry Forecast to 2018

China Pemetrexed Industry Forecast to 2018 | business Research report | Scoop.it

Investigation Report on China Pemetrexed Market, 2009-2018 published in Feb 2014 Available for US $ 1800 at ChinaMarketResearchReports.com - Buy Now or Inquire about this report online.

Ruth Weigle's insight:

The report “Investigation Report on China Pemetrexed Market, 2009-2018″ by China Research and Intelligence is now available at chinamarketresearchreports.com. Contact sales@chinamarketresearchreports.com with Research Report on Investigation Report on China Pemetrexed Market, 2009-2018 in subject line and your contact details to purchase this report or get your questions answered.

The collection of ‘Life Sciences’ market research reports has a new addition of “Investigation Report on China Pemetrexed Market, 2009-2018”On chinamarketresearchreports.com . Pemetrexed, originally developed by Eli Lilly and Company, is a multitargeted antimetabolite antitumor drug. This product is with huge growth potential in the market.

Approved by FDA in February 2004, pemetrexed is to treat unresectable malignant pleural mesothelioma with cisplatin. It is the first drug approved by FDA to treat the disease. In August 2004 pemetrexed was approved as a secondline drug for local or metastatic nonsmall cell lung cancer.

So far pemetrexed (brand name "Alimta") has been approved to more than 60 countries worldwide. The product has been a best seller of Eli Lilly and Company since it was launched, and its sales value keeps increasing year after year. The CAGR of sales value of pemetrexed was 50.6% from 2004 to 2011. The sales value was only USD 140 million in 2004 and reached USD 460 million in 2005. In 2011, it grew rapidly to USD 2.46 billion.

Inquire this Report before buying @ http://www.chinamarketresearchreports.com/contacts/inquire-before-buy.php?name=114730 .

In the field of antitumor drugs in China, antimetabolic drug is one of the most common types among traditional antitumor chemotherapy drugs. Market size of pemetrexed in China has increased rapidly in recent years. The CAGR of its sales value exceeded 70% from 2006 to 2013.

Pemetrexed was approved to clinical use in China in 2004. It was approved to China in 2005 to treat malignant pleural mesothelioma. As a multitargeted antimetabolite antitumor drug, pemetrexed can treat nonsmall cell lung cancer, pancreatic cancer and breast cancer with little side effect. Mechanism of pemetrexed is better than traditional antifolate drugs with great competitiveness in the field.

Hansoh Pharmaceutical and Qilu Pharmaceutical were approved to produce APIs and preparation of this drug respectively in 2005 and 2006. Seeing the great future in the market, a large number of manufacturers start to produce the drug. In 2005, many domestic manufacturers began to apply for the production of raw materials and injections. The competition becomes more intense every day.

Complete report spread across [40] pages available @ http://www.chinamarketresearchreports.com/114730.html . Read more on “Investigation Report on China Pemetrexed Market, 2009-2018” report below.

From 2005 to 2010, Eli Lilly and Company occupied most of Chinese sample hospital market. However, Qilu Pharmaceutical and Hansoh Pharmaceutical has caught up with Eli Lilly and Company since 2011. The main reason is that drugs made within the country seize more market share with relatively low price. As a result, the market is mostly occupied by Qilu Pharmaceutical, Hansoh Pharmaceutical and Eli Lilly and Company.

By the end of 2013, over 10 manufacturers in China have been approved to produce pemetrexed in China by SFDA. It is estimated that the pemetrexed market in China will become increasingly competitive in the future. As environment pollution intensifies, population aging increases and lifestyle changes, incidence of cancer in China keeps rising, leading to rapid growth in antitumor drug market in China.

Through this report, the readers can acquire the following information:

Market Share of Major Pemetrexed Manufacturers in Sample Hospitals in ChinaSales Price of Pemetrexed in China Hospital MarketMajor Pemetrexed Manufacturers in ChinaShare of Pemetrexed in Different Dosage Forms in China Hospital MarketIncidence of Cancer in ChinaManufacturing Schedule of Pemetrexed generic drugProspect of China Pemetrexed Market

The following enterprises and people are recommended to purchase this report:

Pemetrexed APIs and Finished Product ManufacturersMedical InstitutionsInvestors/Research Institutes Focusing on Pemetrexed Market

For further information on “Investigation Report on China Pemetrexed Market, 2009-2018” report OR for any other business research / market intelligence need on the ‘Life Sciences’ market (http://www.chinamarketresearchreports.com/cat/life-sciences.html .), contact sales@chinamarketresearchreports.com / Call +1 888 391 5441.

more...
No comment yet.
Scooped by Ruth Weigle
Scoop.it!

2017 United Kingdom Soups Industry Forecasts and Market Size

2017 United Kingdom Soups Industry Forecasts and Market Size | business Research report | Scoop.it
The Future of the Soups Market in the United Kingdom to 2017: Market Size, Distribution and Brand Share, Key Events and Competitive Landscape is a market research report available at US $1250 for a Single User PDF License from RnR Market Research Reports Library.
Ruth Weigle's insight:

The Report “The Future of the Soups Market in the United Kingdom to 2017: Market Size, Distribution and Brand Share, Key Events and Competitive Landscape″ by Canadean is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with “The Future of the Soups Market in the United Kingdom to 2017: Market Size, Distribution and Brand Share, Key Events and Competitive Landscape″ in subject line and your contact details to purchase this report or get your questions answered.

 

The Future of the Soups Market in the United Kingdom to 2017: Market Size, Distribution and Brand Share, Key Events and Competitive Landscape” is the result of Researcher’s  extensive market and company research. This report presents detailed analysis on the Soups consumption trends in the United Kingdom, historic and forecast Soups consumption volumes and values at market and category level. It also provides indispensable data on brand share, distribution channels, profiles of companies active in the global Soups market along with latest industry news, in addition to mergers & acquisitions. This report brings together Researcher Intelligence’s research, modeling, and analysis expertise in order to develop uniquely detailed market data. This allows domestic and foreign companies to identify the market dynamics to account for Soups sales overall and to know which categories and segments are showing growth in the coming years.

 

Purchase this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=152654 .

Introduction and Landscape


Why was the report written?
This report provides authoritative and granular data on the Soups market in the United Kingdom and, in doing so fills the gaps in marketers’ understanding of trends and the components of change behind them.

 Based upon extensive primary and secondary research to provide comprehensive and granular data, this report allows marketers to confidently update their strategic and tactical plans.

Marketers need data on volume and value changes, brand dynamics and distribution trends in order to effectively plan strategies.

 

Complete report is available @ http://www.rnrmarketresearch.com/the-future-of-the-soups-market-in-the-united-kingdom-to-2017-market-size-distribution-and-brand-share-key-events-and-competitive-landscape-market-report.html . Read more on “The Future of the Soups Market in the United Kingdom to 2017: Market Size, Distribution and Brand Share, Key Events and Competitive Landscape” report below.

 

What are the key drivers behind recent market changes?
This report examines the components of change in the market by looking at historic and future growth patterns, including the effects of consumers’ behavior on total volumes, values, brands selected and types of product chosen.

 

What makes this report unique and essential to read?
The report provides the latest, detailed data on dynamics in the United Kingdom Soups market, providing marketers with the essential data to understand their own, and their competitors’ position in the market and the information to accurately identify where to compete in the future.

 

Key Features and Benefits
Detailed category coverage is provided, covering three product segments that include:

• Ambient Soup
• Chilled soup
• Dried soup
• Frozen Soup
• UHT Soup

Detailed product sales segmentation (for both volumes and values) is provided, including brand data, and sales by distribution channel, at the product category level.

Future forecasts allow marketers to understand the future pattern of market trends from winners and losers to category dynamics and thereby quickly and easily identify the key areas in which they want to compete in the future.

Profiles of companies active in the global Soups market along with latest industry news and mergers & acquisitions.

 

Key Market Issues

Enhance your understanding of the value and volume growth dynamics of the Soups market in the United Kingdom.

Promote growth in your business with detailed product sales for both volumes and values, as well as sales by distribution channel at the product category level.

Identify the future pattern of market trends, from winners and losers to category dynamics; and thereby quickly and easily indentify the key areas in which they want to compete in the future.
 Familiarize yourself with the detailed profiles of companies active in the global Soups market.
 Improve your knowledge of the latest industry news and mergers & acquisitions.

 

For further information on “The Future of the Soups Market in the United Kingdom to 2017: Market Size, Distribution and Brand Share, Key Events and Competitive Landscape” report OR for any other business research / market intelligence need on the ‘Health & Natural Foods’ market (http://www.rnrmarketresearch.com/reports/food-beverage/food/health-natural-foods .), contact sales@rnrmarketresearch.com / Call +1 888 391 5441.

 

About Us:

RnRMarketResearch.com is an online market research reports library of 250,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers. RnR Market Research also offers company data, country profiles, trends, information and analysis on the sector of your interest.

 

You can also reach us @

http://rnrmarketresearch.blogspot.in/

http://www.rnrmarketresearch.com/blog/

http://www.facebook.com/pages/RnR-Market-Research/413488545356345

https://plus.google.com/u/0/104156468549256253075/

https://twitter.com/#!/RnRMR

http://www.dailymotion.com/rnrmarketresearch

http://www.youtube.com/user/rnrmarketresearch

http://www.slideshare.net/rnrmarketresearch3/

more...
No comment yet.
Scooped by Ruth Weigle
Scoop.it!

2022 Italy Obesity Market Forecasts and Analysis

PharmaPoint: Obesity - Italy Drug Forecast and Market Analysis to 2022 is a market research report available at US $4995 for a Single User PDF License from RnR Market Research Reports Library.
Ruth Weigle's insight:

The Report “PharmaPoint: Obesity – Italy Drug Forecast and Market Analysis to 2022″ by GlobalData is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with “PharmaPoint: Obesity – Italy Drug Forecast and Market Analysis to 2022″ in subject line and your contact details to purchase this report or get your questions answered.

After a more than decade long dormancy, the Obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade.

The Italian obesity drug market was valued at approximately $31m in 2012. The projected drivers of sales growth include the launch of Victoza, which was originally indicated for type 2 diabetes treatment, but will eventually available for the treatment of the obese population and the rise in obesity-related comorbidities. For the treatment of overweight and obesity, the Italian pharmaceutical market currently has only Xenical and its generic, the use of which is on the decline.

Request Sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=150299 .

Scope

Overview of Obesity including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.Detailed information on the key drugs in Italy including product description, safety and efficacy profiles as well as a SWOT analysis.Sales forecast for the top drugs in Italy from 2012-2022.Analysis of the impact of key events as well the drivers and restraints affecting the Italy Obesity market.

Complete report is available @ http://www.rnrmarketresearch.com/pharmapoint-obesity-italy-drug-forecast-and-market-analysis-to-2022-market-report.html . Read more on “PharmaPoint: Obesity – Italy Drug Forecast and Market Analysis to 2022” report below.

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return.Stay ahead of the competition by understanding the changing competitive landscape for Obesity.Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.Make more informed business decisions from insightful and in-depth analysis of drug performance.Obtain sales forecast for drugs from 2012-2022 in Italy.

Table of Contents

1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 9

2 Introduction 10
2.1 Catalyst 11
2.2 Related Reports 12

3 Disease Overview 14
3.1 Etiology and Pathophysiology 16
3.1.1 Etiology 16
3.1.2 Pathophysiology 17
3.1.3 Prognosis 17
3.1.4 Quality of Life 18
3.2 Symptoms 18

4 Disease Management 19
4.1 Treatment Overview 19
4.2 Italy 24
4.2.1 Diagnosis 24
4.2.2 Clinical Practice 26

5 Competitive Assessment 29
5.1 Overview 29
5.2 Strategic Competitor Assessment 33
5.3 Product Profiles: Drugs 35
5.3.1 Xenical (orlistat) 35
5.3.2 Belviq (lorcaserin) 38
5.3.3 Oblean (cetilistat) 43

6 Opportunity and Unmet Need 46
6.1 Overview 46
6.2 A Drug with Greater Than 10% Average Weight Loss 47
6.2.1 Unmet Need 47
6.2.2 Gap Analysis 48
6.2.3 Opportunity 49
6.3 A Drug with Increased Safety and Tolerability 49
6.3.1 Unmet Need 49
6.3.2 Gap Analysis 50
6.3.3 Opportunity 50
6.4 Reimbursement by Private and Public Payers 50
6.4.1 Unmet Need 50
6.4.2 Gap Analysis 52
6.4.3 Opportunity 52
6.5 Increased Physician Education 52
6.5.1 Unmet Need 52
6.5.2 Gap Analysis 53
6.5.3 Opportunity 53
6.6 Increased Drug-Treatment Rate 54
6.6.1 Unmet Need 54
6.6.2 Gap Analysis 54
6.6.3 Opportunity 55
6.7 Improved Guidelines 55
6.7.1 Unmet Need 55
6.7.2 Gap Analysis 56
6.7.3 Opportunity 56
6.8 Improved Approach to Diagnosis 56
6.8.1 Unmet Need 56
6.8.2 Gap Analysis 57
6.8.3 Opportunity 57

7 Pipeline Assessment 58
7.1 Overview 58
7.2 Promising Drugs in Clinical Development 61
7.2.1 Contrave 64
7.2.2 Victoza (liraglutide) 69
7.2.3 Velneperit 74
7.2.4 Empatic 78

8 Market Outlook 83
8.1 Italy 84
8.1.1 Forecast 84
8.1.2 Key Events 88
8.1.3 Drivers and Barriers 89

9 Appendix 91
9.1 Bibliography 91
9.2 Abbreviations 98
9.3 Research Methodology 100
9.4 Forecasting Methodology 100
9.4.1 Percent Drug-Treated Obesity Patients 101
9.4.2 Drugs Included in Each Therapeutic Class 101
9.4.3 Launch and Patent Expiry Dates 102
9.4.4 General Pricing Assumptions 102
9.4.5 Individual Drug Assumptions 103
9.4.6 Generic Erosion 106
9.4.7 Pricing of Pipeline Agents 106
9.5 Physicians, Specialists, and Payers Included in This Study 107
9.6 About the Authors 110
9.6.1 Analysts 110
9.6.2 Therapy Director - CVMD and Infectious Disease 111
9.6.3 Director - Medical Devices 111
9.6.4 Global Head of Healthcare 112
9.8 Disclaimer 113

 

For further information on “PharmaPoint: Obesity – Italy Drug Forecast and Market Analysis to 2022” report OR for any other business research / market intelligence need on the ‘Obesity Drugs’ market (http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/obesity-drugs .), contact sales@rnrmarketresearch.com / Call +1 888 391 5441.

 

About Us:

RnRMarketResearch.com is an online market research reports library of 250,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers. RnR Market Research also offers company data, country profiles, trends, information and analysis on the sector of your interest.

 

You can also reach us @

http://rnrmarketresearch.blogspot.in/

http://www.rnrmarketresearch.com/blog/

http://www.facebook.com/pages/RnR-Market-Research/413488545356345

https://plus.google.com/u/0/104156468549256253075/

https://twitter.com/#!/RnRMR

http://www.dailymotion.com/rnrmarketresearch

http://www.youtube.com/user/rnrmarketresearch

http://www.slideshare.net/rnrmarketresearch3/

more...
No comment yet.
Scooped by Ruth Weigle
Scoop.it!

2022 France Obesity Market Forecasts and Analysis

2022 France Obesity Market Forecasts and Analysis | business Research report | Scoop.it

PharmaPoint: Obesity - France Drug Forecast and Market Analysis to 2022 is a market research report available at US $4995 for a Single User PDF License from RnR Market Research Reports Library.

Ruth Weigle's insight:

The Report “PharmaPoint: Obesity – France Drug Forecast and Market Analysis to 2022″ by GlobalData is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with “PharmaPoint: Obesity – France Drug Forecast and Market Analysis to 2022″ in subject line and your contact details to purchase this report or get your questions answered.

After a more than decade long dormancy, the Obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade.

The French obesity drug market was valued at approximately $41m in 2012. The market is a severely underserved space, with only Xenical and its generic as the sole therapy for chronic weight management. Due to the high cost of therapy, most patients have been taking generic orlistat. With a progressively more expansive view on the treatment of obesity with pharmacological intervention, Researcher forecasts the arrival of two promising therapies in 2015.

Request Sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=150297 .

Scope

Overview of Obesity including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.Detailed information on the key drugs in France including product description, safety and efficacy profiles as well as a SWOT analysis.Sales forecast for the top drugs in France from 2012-2022.Analysis of the impact of key events as well the drivers and restraints affecting the France Obesity market.

Complete report is available @ http://www.rnrmarketresearch.com/pharmapoint-obesity-france-drug-forecast-and-market-analysis-to-2022-market-report.html . Read more on “PharmaPoint: Obesity – France Drug Forecast and Market Analysis to 2022” report below.

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return.Stay ahead of the competition by understanding the changing competitive landscape for Obesity.Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.Make more informed business decisions from insightful and in-depth analysis of drug performance.Obtain sales forecast for drugs from 2012-2022 in France.

Table of Contents

1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 9

2 Introduction 10
2.1 Catalyst 11
2.2 Related Reports 12

3 Disease Overview 14
3.1 Etiology and Pathophysiology 16
3.1.1 Etiology 16
3.1.2 Pathophysiology 17
3.1.3 Prognosis 17
3.1.4 Quality of Life 18
3.2 Symptoms 18

4 Disease Management 19
4.1 Treatment Overview 19
4.2 France 24
4.2.1 Diagnosis 24
4.2.2 Clinical Practice 26

5 Competitive Assessment 29
5.1 Overview 29
5.2 Strategic Competitor Assessment 33
5.3 Product Profiles: Drugs 35
5.3.1 Xenical (orlistat) 35
5.3.2 Belviq (lorcaserin) 38
5.3.3 Oblean (cetilistat) 43

6 Opportunity and Unmet Need 46
6.1 Overview 46
6.2 A Drug with Greater Than 10% Average Weight Loss 47
6.2.1 Unmet Need 47
6.2.2 Gap Analysis 48
6.2.3 Opportunity 49
6.3 A Drug with Increased Safety and Tolerability 49
6.3.1 Unmet Need 49
6.3.2 Gap Analysis 50
6.3.3 Opportunity 50
6.4 Reimbursement by Private and Public Payers 50
6.4.1 Unmet Need 50
6.4.2 Gap Analysis 52
6.4.3 Opportunity 52
6.5 Increased Physician Education 52
6.5.1 Unmet Need 52
6.5.2 Gap Analysis 53
6.5.3 Opportunity 53
6.6 Increased Drug-Treatment Rate 54
6.6.1 Unmet Need 54
6.6.2 Gap Analysis 54
6.6.3 Opportunity 55
6.7 Improved Guidelines 55
6.7.1 Unmet Need 55
6.7.2 Gap Analysis 56
6.7.3 Opportunity 56
6.8 Improved Approach to Diagnosis 56
6.8.1 Unmet Need 56
6.8.2 Gap Analysis 57
6.8.3 Opportunity 57

7 Pipeline Assessment 58
7.1 Overview 58
7.2 Promising Drugs in Clinical Development 61
7.2.1 Contrave 64
7.2.2 Victoza (liraglutide) 69
7.2.3 Velneperit 74
7.2.4 Empatic 78

8 Market Outlook 83
8.1 France 84
8.1.1 Forecast 84
8.1.2 Key Events 88
8.1.3 Drivers and Barriers 89

9 Appendix 91
9.1 Bibliography 91
9.2 Abbreviations 97
9.3 Research Methodology 99
9.4 Forecasting Methodology 99
9.4.1 Percent Drug-Treated Obesity Patients 100
9.4.2 Drugs Included in Each Therapeutic Class 100
9.4.3 Launch and Patent Expiry Dates 101
9.4.4 General Pricing Assumptions 101
9.4.5 Individual Drug Assumptions 102
9.4.6 Generic Erosion 105
9.4.7 Pricing of Pipeline Agents 105
9.5 Physicians, Specialists, and Payers Included in This Study 106
9.6 About the Authors 109
9.6.1 Analysts 109
9.6.2 Therapy Director - CVMD and Infectious Disease 110
9.6.3 Director - Medical Devices 110
9.6.4 Global Head of Healthcare 111
9.8 Disclaimer 112

 

For further information on “PharmaPoint: Obesity – France Drug Forecast and Market Analysis to 2022” report OR for any other business research / market intelligence need on the ‘Obesity Drugs market (http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/obesity-drugs .), contact sales@rnrmarketresearch.com / Call +1 888 391 5441.

 

About Us:

RnRMarketResearch.com is an online market research reports library of 250,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers. RnR Market Research also offers company data, country profiles, trends, information and analysis on the sector of your interest.

 

You can also reach us @

http://rnrmarketresearch.blogspot.in/

http://www.rnrmarketresearch.com/blog/

http://www.facebook.com/pages/RnR-Market-Research/413488545356345

https://plus.google.com/u/0/104156468549256253075/

https://twitter.com/#!/RnRMR

http://www.dailymotion.com/rnrmarketresearch

http://www.youtube.com/user/rnrmarketresearch

http://www.slideshare.net/rnrmarketresearch3/

more...
No comment yet.